Tripathi Brajendra Kumar, Srivastava Arvind Kumar
Division of Biochemistry, Central Drug Research Institute, Lucknow-226001, India.
Med Sci Monit. 2006 Jul;12(7):RA130-47. Epub 2006 Jun 28.
Diabetes mellitus has now assumed epidemic proportions in many countries of the world. With the present population of 19.4 million diabetics, and approximately 60 million by the year 2025, India would rank first in its share of the global burden of diabetes. Diabetes mellitus is characterized by derangement in carbohydrate, protein, and fat metabolism caused by complete or relative insufficiency of insulin secretion and/or insulin action. There are two main forms of diabetes, type 1 (insulin-dependent diabetes mellitus) and type 2 (non-insulin-dependent diabetes mellitus). Insulin sensitizers (thiazolidinediones), new-generation insulin secretagogue (glimepiride), acarbose, and designer insulin (lispro and aspart) have enormously helped in achieving better metabolic control. Despite the great strides that have been made in the understanding and management of type 2 diabetes, insulin resistance and diabetes-related complications are increasing unabated. The present review not only updates our knowledge in delineating the molecular mechanism(s) causal to insulin sensitivity or resistance, but also provides clues for the prognosis of diabetes and its better management.
糖尿病在世界许多国家已呈流行态势。印度目前有1940万糖尿病患者,到2025年预计将达约6000万,届时印度在全球糖尿病负担中所占份额将位居首位。糖尿病的特征是由于胰岛素分泌完全或相对不足和/或胰岛素作用紊乱而导致碳水化合物、蛋白质和脂肪代谢失调。糖尿病主要有两种类型,1型(胰岛素依赖型糖尿病)和2型(非胰岛素依赖型糖尿病)。胰岛素增敏剂(噻唑烷二酮类)、新一代胰岛素促泌剂(格列美脲)、阿卡波糖以及速效胰岛素(赖脯胰岛素和门冬胰岛素)极大地有助于实现更好的代谢控制。尽管在2型糖尿病的认识和管理方面取得了巨大进展,但胰岛素抵抗和糖尿病相关并发症仍在持续增加。本综述不仅更新了我们在阐明胰岛素敏感性或抵抗的分子机制方面的知识,还为糖尿病的预后及其更好的管理提供了线索。